Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma

Gene Therapy

Volumn 22, Issue 2, 2015, Pages 146-154

  Shimazu, Y ^a   Kurozumi, K ^a   Ichikawa, T ^a   Fujii, K ^a   Onishi, M ^a   Ishida, J ^a   Oka, T ^a   Watanabe, M ^b   Nasu, Y ^b   Kumon, H ^a   Date, I ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHAVBETA5 INTEGRIN; ANTINEOPLASTIC AGENT; BETA CATENIN; CASPASE 8; CASPASE 9; CILENGITIDE; DICKKOPF 3 PROTEIN; GENE THERAPY AGENT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; CASP8 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN; CYCLOPEPTIDE; DKK3 PROTEIN, HUMAN; INTEGRIN; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; CANCER GENE THERAPY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; GLIOMA CELL; GLIOMA CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SURVIVAL TIME; THERAPY EFFECT; VIRAL GENE DELIVERY SYSTEM; WNT SIGNALING PATHWAY; ADENOVIRIDAE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BRAIN NEOPLASMS; DRUG SCREENING; GENE SILENCING; GENE THERAPY; GENETIC TRANSDUCTION; GENETICS; GLIOMA; METABOLISM; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; TUMOR CELL LINE;

ADENOVIRIDAE; MUS;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASTROCYTES; BRAIN NEOPLASMS; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENETIC THERAPY; GLIOMA; HUMANS; INTEGRINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE, INBRED BALB C; MICE, NUDE; PEPTIDES, CYCLIC; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922402325     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.100     Document Type: Article

References (36)

1. Penas-Prado M, Gilbert MR. Molecularly targeted therapies for malignant gliomas: advances and challenges. Expert Rev Anticancer Ther 2007; 7: 641-661.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
3. Chatterjee S, Matsumura A, Schradermeier J, Gillespie GY. Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. J Neurooncol 2000; 46: 135-144.
4. Mizobuchi Y, Matsuzaki K, Kuwayama K, Kitazato K, Mure H, Kageji T et al. REIC/Dkk-3 induces cell death in human malignant glioma. Neuro-Oncology 2008; 10: 244-253.
5. Abarzua F, Sakaguchi M, Takaishi M. Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase. Cancer Res 2005; 65: 9617-9622.
6. Wang J, Shou J, Chen X. Dickkopf-1: an inhibitor of the Wnt signaling pathway, is induced by p53. Oncogene 2000; 19: 1843-1848.
7. Varner JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol 1996; 8: 724-730.
8. Varner JA, Cheresh DA. Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Import Adv Oncol 1996; 69-87.
9. Varner JA, Emerson DA, Juliano RL. Integrin alpha 5 beta 1 expression negatively regulates cell growth: reversal by attachment to fibronectin. Mol Biol Cell 1995; 6: 725-740.
10. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270: 1500-1502.
11. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569-571.
12. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164.
13. Hodivala-Dilke KM, Reynolds AR, Reynolds LE. Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res 2003; 314: 131-144.
14. Leavesley DI, Ferguson GD, Wayner EA, Cheresh DA. Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol 1992; 117: 1101-1107.
15. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 2001; 48: 151-157.
16. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R et al. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005; 11: 6270-6279.
17. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002; 62: 4263-4272.
18. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycineaspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008; 26: 5610-5617.
19. Tentori L, Dorio AS, Muzi A, Lacal PM, Ruffini F, Navarra P et al. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol Rep 2008; 19: 1039-1043.
20. Onishi M, Ichikawa T, Kurozumi K, Fujii K, Yoshida K, Inoue S et al. Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models. Neuropathology 2013; 33: 162-174.
21. Onishi M, Kurozumi K, Ichikawa T, Michiue H, Fujii K, Ishida J et al. Gene expression profiling of the anti-glioma effect of Cilengitide. SpringerPlus 2013; 2: 160.
22. Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 2009; 124: 2719-2727.
23. Fujii K, Kurozumi K, Ichikawa T, Onishi M, Shimazu Y, Ishida J et al. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus. Cancer Gene Ther 2013; 20: 437-444.
24. Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 2007; 99: 1768-1781.
25. Kurozumi K, Ichikawa T, Onishi M, Fujii K, Date I. Cilengitide treatment for malignant glioma: current status and future direction. Neurol Medico-Chirurg 2012; 52: 539-547.
26. Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, Mayo MW et al. Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol 2001; 152: 87-96.
27. Tentori L, Dorio A, Muzi A, Lacal PM, Ruffini F, Navarra P et al. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol Rep 2008; 19: 1039-1043.
28. Abdollahi A, Griggs D, Zieher H. Inhibition of αvβ3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005; 11: 6270-6279.
29. Alghisi GC, Ponsonnet L, Ruegg C. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 2009; 4: e4449.
30. Burkhalter RJ, Symowicz J, Hudson LG, Gottardi CJ, Stack MS. Integrin regulation of beta-catenin signaling in ovarian carcinoma. J Biol Chem 2011; 286: 23467-23475.
31. Howard JC, Varallo VM, Ross DC, Roth JH, Faber KJ, Alman B et al. Elevated levels of beta-catenin and fibronectin in three-dimensional collagen cultures of Dupuytren's disease cells are regulated by tension in vitro. BMC Musculoskelet Disord 2003; 4: 16.
32. Kashiwakura Y, Ochiai K, Watanabe M, Abarzua F, Sakaguchi M, Takaoka M et al. Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis. Cancer Res 2008; 68: 8333-8341.
33. Than SS, Kataoka K, Sakaguchi M, Murata H, Abarzua F, Taketa C et al. Intraperitoneal administration of an adenovirus vector carrying REIC/Dkk-3 suppresses peritoneal dissemination of scirrhous gastric carcinoma. Oncol Rep 2011; 25: 989-995.
34. Edamura K, Nasu Y, Takaishi M, Kobayashi T, Abarzua F, Sakaguchi M et al. Adenovirus-mediated REIC/Dkk-3 gene transfer inhibits tumor growth and metastasis in an orthotopic prostate cancer model. Cancer Gene Ther 2007; 14: 765-772.
35. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1100-1108.
36. Matsuzaki T, Yashiro M, Kaizaki R, Yasuda K, Doi Y, Sawada T et al. Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci 2009; 100: 2402-2410.